Announcements

  1. Call for Papers: Special Issue on "Innovations in Cancer Immunotherapy"

The Pacific Journal of Oncology & Immunotherapy (PJOI) is excited to announce a Call for Papers for our upcoming Special Issue titled "Innovations in Cancer Immunotherapy." This special edition will highlight the latest advancements and breakthrough therapies in cancer immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapies, and novel cancer vaccines. We invite researchers, clinicians, and industry experts to submit original research, comprehensive reviews, and cutting-edge case studies addressing key topics such as personalized immunotherapy, resistance mechanisms, combination therapies, and emerging immunotherapeutic strategies. Submissions that offer novel insights and practical applications are highly encouraged. Authors can submit their manuscripts through the PJOI online submission portal.

 

  1. Welcome Our New Editorial Board Member, Dr. Sarah Williams

We are thrilled to welcome Dr. Sarah Williams to the Editorial Board of The Pacific Journal of Oncology & Immunotherapy (PJOI). Dr. Williams is an esteemed leader in the field of oncology and immunotherapy, with a wealth of experience in both academic research and clinical practice. Her pioneering work in cancer immunology and targeted treatments has significantly advanced the understanding of how the immune system can be harnessed to fight cancer. At PJOI, Dr. Williams will provide invaluable expertise to help shape the future of oncology research. We are excited to have her join the team and contribute to the continued success of the journal. Please join us in welcoming Dr. Williams!

 

  1. Upcoming Webinar: "Harnessing the Power of Immunotherapy in Cancer Treatment"

We are pleased to announce an upcoming webinar titled "Harnessing the Power of Immunotherapy in Cancer Treatment." This event will feature world-renowned experts discussing the latest advancements in immunotherapy and its potential to revolutionize cancer treatment. Topics will include immune checkpoint inhibitors, CAR-T cell therapy, and novel immune-modulating approaches. The webinar will also address clinical trial outcomes, challenges in treatment resistance, and the future of personalized immunotherapy. This is an excellent opportunity for researchers, clinicians, and healthcare professionals to gain firsthand insights from experts. Stay tuned for more details and register to secure your spot!

 

  1. New Issue Release: "Targeted Therapies and Precision Oncology"

We are excited to announce the release of the latest issue of PJOI, featuring a special focus on "Targeted Therapies and Precision Oncology." This issue brings together groundbreaking research on the role of targeted therapies in cancer treatment, emphasizing how personalized approaches are transforming patient care. Articles in this issue cover topics such as the development of molecular-targeted drugs, the integration of genomics in clinical practice, and innovative strategies for overcoming resistance to targeted therapies. We are grateful to all contributing authors for their outstanding research, and we invite you to explore this cutting-edge issue available online now.

 

  1. Recognizing Our Exceptional Peer Reviewers

The Pacific Journal of Oncology & Immunotherapy (PJOI), we take this opportunity to recognize and express our gratitude to our exceptional peer reviewers whose valuable contributions have been instrumental in maintaining the highest standards of academic excellence. Their insightful reviews and timely feedback ensure the quality of the research published in our journal. This year, we are pleased to honor the following reviewers for their outstanding dedication:

  • Dr. Emily Thompson
  • Prof. Robert Martin
  • Dr. David Kim
  • Prof. Laura White
  • Dr. James Carter

 

As a token of our appreciation, these distinguished reviewers will receive complimentary subscriptions to the journal and exclusive invitations to upcoming events. We deeply value their continued support in advancing oncology and immunotherapy research and look forward to their ongoing contributions to PJOI’s success.